Patient characteristics of study cohort
Patient characteristics . | Number, (%) (cohort, N = 96) . |
---|---|
Age at initial PE (y) | |
<1 | 2 (2) |
1-5 | 2 (2) |
5-12 | 9 (9) |
>12 | 84 (88) |
Sex | |
Male | 39 (41) |
Female | 57 (59) |
Thrombosis risk factors | |
BMI ≥ 30 | 38 (40) |
Combined oral contraceptives | 27 (28) |
Central venous catheter | 20 (21) |
Identified thrombophilia | 18 (19) |
FVL | 9 (9) |
PGM | 3 (3) |
APS | 3 (3) |
Protein S deficiency | 1 (1) |
FVL + PGM | 1 (1) |
Concurrent extremity VTE | 13 (14) |
VTE history | 9 (9) |
Recent surgery | 9 (9) |
Recent infection | 6 (6) |
Immobility because of injury | 3 (3) |
Medical conditions | |
Congenital heart disease | 11 (11) |
Autoimmune disease | 9 (9) |
Asthma | 7 (7) |
May Thurner syndrome | 4 (4) |
Renal disease | 3 (3) |
Other | 27 (28) |
None | 31 (32) |
Risk level of initial PE | |
Low risk | 76 (78) |
Intermediate risk | 19 (20) |
High risk | 2 (2) |
Patient characteristics . | Number, (%) (cohort, N = 96) . |
---|---|
Age at initial PE (y) | |
<1 | 2 (2) |
1-5 | 2 (2) |
5-12 | 9 (9) |
>12 | 84 (88) |
Sex | |
Male | 39 (41) |
Female | 57 (59) |
Thrombosis risk factors | |
BMI ≥ 30 | 38 (40) |
Combined oral contraceptives | 27 (28) |
Central venous catheter | 20 (21) |
Identified thrombophilia | 18 (19) |
FVL | 9 (9) |
PGM | 3 (3) |
APS | 3 (3) |
Protein S deficiency | 1 (1) |
FVL + PGM | 1 (1) |
Concurrent extremity VTE | 13 (14) |
VTE history | 9 (9) |
Recent surgery | 9 (9) |
Recent infection | 6 (6) |
Immobility because of injury | 3 (3) |
Medical conditions | |
Congenital heart disease | 11 (11) |
Autoimmune disease | 9 (9) |
Asthma | 7 (7) |
May Thurner syndrome | 4 (4) |
Renal disease | 3 (3) |
Other | 27 (28) |
None | 31 (32) |
Risk level of initial PE | |
Low risk | 76 (78) |
Intermediate risk | 19 (20) |
High risk | 2 (2) |
FVL, factor V Leiden mutation; PGM, prothrombin gene mutation.